Back to Search Start Over

ARDS Clinical Practice Guideline 2021

Authors :
Sadatomo Tasaka
Shinichiro Ohshimo
Muneyuki Takeuchi
Hideto Yasuda
Kazuya Ichikado
Kenji Tsushima
Moritoki Egi
Satoru Hashimoto
Nobuaki Shime
Osamu Saito
Shotaro Matsumoto
Eishu Nango
Yohei Okada
Kenichiro Hayashi
Masaaki Sakuraya
Mikio Nakajima
Satoshi Okamori
Shinya Miura
Tatsuma Fukuda
Tadashi Ishihara
Tetsuro Kamo
Tomoaki Yatabe
Yasuhiro Norisue
Yoshitaka Aoki
Yusuke Iizuka
Yutaka Kondo
Chihiro Narita
Daisuke Kawakami
Hiromu Okano
Jun Takeshita
Keisuke Anan
Satoru Robert Okazaki
Shunsuke Taito
Takuya Hayashi
Takuya Mayumi
Takero Terayama
Yoshifumi Kubota
Yoshinobu Abe
Yudai Iwasaki
Yuki Kishihara
Jun Kataoka
Tetsuro Nishimura
Hiroshi Yonekura
Koichi Ando
Takuo Yoshida
Tomoyuki Masuyama
Masamitsu Sanui
ARDS Clinical Practice Guideline 2021 committee from the Japanese Society of Intensive Care Medicine, the Japanese Respiratory Society, and the Japanese Society of Respiratory Care Medicine
Source :
Journal of Intensive Care, Vol 10, Iss 1, Pp 1-52 (2022)
Publication Year :
2022
Publisher :
BMC, 2022.

Abstract

Abstract Background The joint committee of the Japanese Society of Intensive Care Medicine/Japanese Respiratory Society/Japanese Society of Respiratory Care Medicine on ARDS Clinical Practice Guideline has created and released the ARDS Clinical Practice Guideline 2021. Methods The 2016 edition of the Clinical Practice Guideline covered clinical questions (CQs) that targeted only adults, but the present guideline includes 15 CQs for children in addition to 46 CQs for adults. As with the previous edition, we used a systematic review method with the Grading of Recommendations Assessment Development and Evaluation (GRADE) system as well as a degree of recommendation determination method. We also conducted systematic reviews that used meta-analyses of diagnostic accuracy and network meta-analyses as a new method. Results Recommendations for adult patients with ARDS are described: we suggest against using serum C-reactive protein and procalcitonin levels to identify bacterial pneumonia as the underlying disease (GRADE 2D); we recommend limiting tidal volume to 4–8 mL/kg for mechanical ventilation (GRADE 1D); we recommend against managements targeting an excessively low SpO2 (PaO2) (GRADE 2D); we suggest against using transpulmonary pressure as a routine basis in positive end-expiratory pressure settings (GRADE 2B); we suggest implementing extracorporeal membrane oxygenation for those with severe ARDS (GRADE 2B); we suggest against using high-dose steroids (GRADE 2C); and we recommend using low-dose steroids (GRADE 1B). The recommendations for pediatric patients with ARDS are as follows: we suggest against using non-invasive respiratory support (non-invasive positive pressure ventilation/high-flow nasal cannula oxygen therapy) (GRADE 2D), we suggest placing pediatric patients with moderate ARDS in the prone position (GRADE 2D), we suggest against routinely implementing NO inhalation therapy (GRADE 2C), and we suggest against implementing daily sedation interruption for pediatric patients with respiratory failure (GRADE 2D). Conclusions This article is a translated summary of the full version of the ARDS Clinical Practice Guideline 2021 published in Japanese (URL: https://www.jsicm.org/publication/guideline.html ). The original text, which was written for Japanese healthcare professionals, may include different perspectives from healthcare professionals of other countries.

Details

Language :
English
ISSN :
20520492
Volume :
10
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Journal of Intensive Care
Publication Type :
Academic Journal
Accession number :
edsdoj.545de85b3fbe4f2aa57e03cec29b454a
Document Type :
article
Full Text :
https://doi.org/10.1186/s40560-022-00615-6